利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

532 条记录 (耗时 0.012 秒)

    NICOTINE CHEWING GUM
    1.
    发明申请
    NICOTINE CHEWING GUM 审中-公开

    公开(公告)号：WO2023067087A1

    公开(公告)日：2023-04-27

    申请号：PCT/EP2022/079258

    申请日：2022-10-20

    申请人： MCNEIL AB

    发明人： EDMAN, Martin ,  NILGARD, Jill

    IPC分类号： A61K31/465 ,  A23G4/20

    摘要： The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine, as well as an extended release and uptake of nicotine. The invention further describes suitable manufacturing processes for such chewing gum formulations, as well as the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

    SOLID ORAL NICOTINE FORMULATION
    2.
    发明申请
    SOLID ORAL NICOTINE FORMULATION 审中-公开

    公开(公告)号：WO2022100806A1

    公开(公告)日：2022-05-19

    申请号：PCT/DK2021/050335

    申请日：2021-11-16

    申请人： FERTIN PHARMA A/S

    发明人： NIELSEN, Kent Albin ,  POULSEN, Jessie

    IPC分类号： A61K31/465 ,  A24B15/16 ,  A24B15/42

    摘要： A solid oral nicotine formulation is disclosed, the formulation comprises a nicotine- ion exchange resin combination, and a salt comprising inorganic divalent cations, wherein the salt has a water-solubility of at least 5 grams per 100 mL of water measured at 25 degrees Celsius, atmospheric pressure and pH 7.0.

    ORAL ANTAGONIST COMPOSITIONS FOR NICOTINE BURNING RELIEF
    3.
    发明申请
    ORAL ANTAGONIST COMPOSITIONS FOR NICOTINE BURNING RELIEF 审中-公开

    公开(公告)号：WO2022063372A1

    公开(公告)日：2022-03-31

    申请号：PCT/DK2021/050291

    申请日：2021-09-21

    申请人： FERTIN PHARMA A/S

    发明人： ALBIN NIELSEN, Kent

    IPC分类号： A61K31/465 ,  A61K9/00 ,  A61K31/125 ,  A61K31/167 ,  A61K45/06 ,  A61P43/00

    摘要： The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and/or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).

    NEW COMPOSITIONS FOR ORAL OR NASAL USE
    4.
    发明申请
    NEW COMPOSITIONS FOR ORAL OR NASAL USE 审中-公开

    公开(公告)号：WO2021225509A1

    公开(公告)日：2021-11-11

    申请号：PCT/SE2021/050431

    申请日：2021-05-07

    申请人： LIW INNOVATION AB

    发明人： BJÖRKHOLM, Lars ,  BJÖRKHOLM, Johan

    IPC分类号： A61K47/36 ,  A24B15/16 ,  A61K31/352 ,  A61K31/465 ,  A61K47/12 ,  A61P25/34

    摘要： The specification discloses compositions for use in the oral or nasal cavity comprising a biologically active agent, a matrix forming agent comprising alginate and suitable salts thereof, a filling agent and at least one antioxidant that is an effective complex binder. The compositions can further comprise additional excipients such as preservatives, taste or flavour enhancers, pH adjusters, plasticizers and sweeteners. The specification also discloses methods of producing the compositions.

    VERFAHREN ZUR HERSTELLUNG VON WIRKSTOFFVERABREICHUNGSSYSTEMEN MITTELS TAMPONDRUCKVERFAHREN
    6.
    发明申请
    VERFAHREN ZUR HERSTELLUNG VON WIRKSTOFFVERABREICHUNGSSYSTEMEN MITTELS TAMPONDRUCKVERFAHREN 审中-公开

    公开(公告)号：WO2020259765A1

    公开(公告)日：2020-12-30

    申请号：PCT/DE2020/100558

    申请日：2020-06-26

    申请人： LTS LOHMANN THERAPIE-SYSTEME AG

    发明人： HILLE, Thomas ,  BOTZEM, Petra ,  WIONZEK, Albert

    IPC分类号： A61K9/70 ,  A61K31/465

    摘要： Die vorliegende Erfindung betrifft ein Tampondruckverfahren zur Herstellung einer Verabreichungsform für einen pharmazeutischen Wirkstoff, wobei das Verfahren das Bereitstellen eines Substrates der Verabreichungsform und das Übertragen des Wirkstoffs mittels eines Tampons von einem Klischee auf das Substrat umfasst, wobei die Fläche des Klischees größer ist als die Fläche des wirkstoffhaltigen Aufdrucks auf das Substrat. Dieses Verfahren eignet sich insbesondere zur Herstellung von transdermalen therapeutischen Systemen mit flüchtigen Wirkstoffen. Die vorliegende Erfindung betrifft ebenso Anordnungen, mit denen ein solches Verfahren implementiert werde kann.

    AEROSOLISABLE FORMULATION
    7.
    发明申请
    AEROSOLISABLE FORMULATION 审中-公开

    公开(公告)号：WO2020089634A1

    公开(公告)日：2020-05-07

    申请号：PCT/GB2019/053088

    申请日：2019-10-31

    申请人： NICOVENTURES TRADING LIMITED

    发明人： CABOT, Ross

    IPC分类号： A24B15/167 ,  A24F40/10 ,  A61K31/465

    摘要： There is provided an aerosolisable formulation comprising (i) water (ii) nicotine; (iii) at least one acid; and (iv) one or more flavours; and (v) one or more encapsulating materials, wherein the encapsulating material encapsulates at least one of the one or more flavours in preference to protonated nicotine; wherein the molar ratio of (a) encapsulating material encapsulating the one or more flavours to (b) unencapsulated flavours is greater than the molar ratio of (c) encapsulating material encapsulating nicotine to (d) unencapsulated nicotine.

    VAPORISABLE FORMULATION
    8.
    发明申请
    VAPORISABLE FORMULATION 审中-公开

    公开(公告)号：WO2019211629A1

    公开(公告)日：2019-11-07

    申请号：PCT/GB2019/051244

    申请日：2019-05-03

    申请人： NICOVENTURES TRADING LIMITED

    发明人： MATHIE, Klaus ,  MONTSERRAT SANCHEZ PENA, Maria

    IPC分类号： A24F47/00 ,  A61K31/465 ,  C07C29/56

    摘要： There is provided a vaporisable formulation comprising (i) one or more solvents; and (ii) less than about 1 wt % of a cooling agent based on the weight of the vaporisable formulation; wherein the cooling agent volatilises at a higher temperature than menthol at atmospheric pressure. There is also provided a vaporisable formulation comprising (i) one or more solvents; and (ii) less than about 12 wt% of a cooling agent based on the weight of the vaporisable formulation; wherein the cooling agent volatilises at a higher temperature than menthol at atmospheric pressure and is a compound of formula (I) or a salt and/or solvate thereof as defined herein.

    VAGINAL SYSTEMIC DRUG DELIVERY
    9.
    发明申请
    VAGINAL SYSTEMIC DRUG DELIVERY 审中-公开

    公开(公告)号：WO2019201713A1

    公开(公告)日：2019-10-24

    申请号：PCT/EP2019/059126

    申请日：2019-04-10

    申请人： LIGALLI B.V.

    发明人： DE LAAT, Wilhelmus Nicolaas Gerardus Maria

    IPC分类号： A61K31/216 ,  A61K9/00 ,  A61K31/428 ,  A61K31/465 ,  A61K31/485 ,  A61K31/5513 ,  A61K38/00 ,  A61P13/10 ,  A61P25/04 ,  A61P25/16 ,  A61P5/24 ,  A61P9/00 ,  A61P35/00 ,  A61P15/08 ,  A61P3/10

    摘要： The present invention relates to a therapeutically active compound for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring. The present invention further relates to a therapeutically active compound selected from the group consisting of oxybutynin and other anti -muscarinic compounds, gonadotropin-releasing hormone (GnRH) and derivatives, both agonists and antagonists, nitroglycerin and other directly or indirectly acting cGMP enhancers, buprenorphine and other agonistic, antagonistic or partial (ant)agonistic opioids, nicotine and derivatives, lorazepam and other benzodiazepines, insulin and other blood glucose regulating compounds, FSH and other hormones for ovulation stimulation, pramipexol and other dopamine agonists, oxytocin and other hypothalamic peptides for the treatment of a medical condition, wherein the therapeutically active compound is administered in liquid formulation via the vagina by using an intravaginal ring.